



**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**In re Application of:**

Khan et al.

**Serial No.:** 10/029,206

**Filed:** December 21, 2001

**For:** OLIGOPEPTIDE TREATMENT OF  
NF- $\kappa$ B MEDIATED INFLAMMATION

**Confirmation No.:** 5353

**Examiner:** J. Witz

**Group Art Unit:** 1651

**Attorney Docket No.:** 2183-5222US  
(KB/P57494US00)


**Notice of Allowance Mailed:**

July 25, 2006

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail on the date of deposit shown below with sufficient postage and in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

October 17, 2006  
Date

  
Signature

Betty Vowles  
Name (Type/Print)

**AMENDMENT PURSUANT TO 37 C.F.R. § 1.312(a)**

Mail Stop ISSUE FEE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

Please amend the above-referenced application as follows:

**Amendments to the title** appear on page 2 of this paper;

**Remarks** begin on page 3 of this paper.

**Serial No. 10/029,206**

IN THE TITLE:

The title has been amended herein. Pursuant to 37 C.F.R. §§ 1.121 and 1.125 (as amended to date), please amend the title as follows:

OLIGOPEPTIDE TREATMENT OF [[NK-κB]]NF-κB MEDIATED INFLAMMATION